BRPI0618488A2 - proteìnas de fusão de ìntron de fator de crescimento de hepatócito - Google Patents

proteìnas de fusão de ìntron de fator de crescimento de hepatócito Download PDF

Info

Publication number
BRPI0618488A2
BRPI0618488A2 BRPI0618488-0A BRPI0618488A BRPI0618488A2 BR PI0618488 A2 BRPI0618488 A2 BR PI0618488A2 BR PI0618488 A BRPI0618488 A BR PI0618488A BR PI0618488 A2 BRPI0618488 A2 BR PI0618488A2
Authority
BR
Brazil
Prior art keywords
growth factor
hepatocyte growth
fusion proteins
isoforms
intron fusion
Prior art date
Application number
BRPI0618488-0A
Other languages
English (en)
Inventor
Pei Jin
H Michael Shepard
Irene Ni
Original Assignee
Receptor Biologix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptor Biologix Inc filed Critical Receptor Biologix Inc
Publication of BRPI0618488A2 publication Critical patent/BRPI0618488A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)

Abstract

PROTEìNAS DE FUSãO DE ìNTRON DE FATOR DE CRESCIMENTO DE HEPATóCITO. A presente invenção refere-se a isoformas de ligantes, incluindo isoformas de fator de crescimento de hepatócito (HGF) contendo uma porção íntron-codificada e composições farmacêuticas contendo isoformas de HGF. As isoformas de ligante de HGF e composições contendo as mesmas podem ser usadas em métodos de tratamento de doenças, tais como câncer e outras doenças angiogênicas.
BRPI0618488-0A 2005-11-10 2006-10-31 proteìnas de fusão de ìntron de fator de crescimento de hepatócito BRPI0618488A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73560905P 2005-11-10 2005-11-10
PCT/US2006/042607 WO2007058776A2 (en) 2005-11-10 2006-10-31 Hepatocyte growth factor intron fusion proteins

Publications (1)

Publication Number Publication Date
BRPI0618488A2 true BRPI0618488A2 (pt) 2011-08-30

Family

ID=37814245

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618488-0A BRPI0618488A2 (pt) 2005-11-10 2006-10-31 proteìnas de fusão de ìntron de fator de crescimento de hepatócito

Country Status (10)

Country Link
US (1) US20070161081A1 (pt)
EP (1) EP1954714A2 (pt)
JP (1) JP2009515520A (pt)
KR (1) KR20080082629A (pt)
CN (1) CN101356189A (pt)
AU (1) AU2006315825A1 (pt)
BR (1) BRPI0618488A2 (pt)
CA (1) CA2628928A1 (pt)
NO (1) NO20082564L (pt)
WO (1) WO2007058776A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678769B2 (en) 2001-09-14 2010-03-16 Compugen, Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
WO2005016966A2 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
CA2624535A1 (en) 2005-09-30 2007-04-05 Compugen Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
JP2009515521A (ja) * 2005-11-10 2009-04-16 レセプター バイオロジックス， インコーポレイテッド レセプターアイソフォームおよびリガンドアイソフォームの産生のための方法
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
JP5391400B2 (ja) * 2007-10-01 2014-01-15 公益財団法人ヒューマンサイエンス振興財団 α−アクチニン−４遺伝子のコピー数または発現レベルを指標とした膵癌の検出を補助する方法および診断のためのキット
US8247374B2 (en) 2007-11-09 2012-08-21 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
ES2421719T3 (es) * 2008-04-21 2013-09-05 Bio Rad Laboratories Antígeno de gliadina recombinante desamidada
WO2010048588A2 (en) * 2008-10-23 2010-04-29 Massachusetts Institute Of Technology Directed engagement of activating fc receptors
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
EP2701686A4 (en) 2011-04-28 2014-11-05 Stc Unm LIPID BINCHES SUPPORTED ON POROUS NANOPARTICLES (PROTOCELLS) FOR TARGETED ADMINISTRATION, AND METHODS OF USE THEREOF
CN104302780B (zh) * 2011-08-05 2017-04-12 艾克斯-马赛大学 纤维变性易感性il22ra2基因及其用途
ES2688268T3 (es) 2011-12-05 2018-10-31 Bio-Rad Laboratories, Inc. Antígeno de gliadina desamidada recombinante
UA116665C2 (uk) * 2013-07-31 2018-04-25 Емджен Інк. Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15)
JP6240337B2 (ja) 2013-10-22 2017-11-29 バイロメッド カンパニー リミテッド 肝細胞増殖因子の２つ以上のアイソフォームを利用した筋萎縮性側索硬化症の予防又は治療用組成物
US9710451B2 (en) * 2014-06-30 2017-07-18 International Business Machines Corporation Natural-language processing based on DNA computing
CN107531802A (zh) * 2015-01-21 2018-01-02 里尔第大学 来自肝细胞生长因子/散射因子（hgf/sf）的kringle结构域的多聚体化合物
PT3247719T (pt) * 2015-01-21 2019-12-23 Univ Degli Studi Di Pavia Proteínas agonistas do receptor met
WO2017020025A1 (en) 2015-07-29 2017-02-02 Kiick Kristi Thermoresponsive bioconjugates and their controlled delivery of cargo
US10388404B2 (en) 2015-10-27 2019-08-20 International Business Machines Corporation Using machine-learning to perform linear regression on a DNA-computing platform
WO2017120504A1 (en) 2016-01-08 2017-07-13 Durfee Paul N Osteotropic nanoparticles for prevention or treatment of bone metastases
RU2747977C2 (ru) * 2016-03-17 2021-05-18 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ получения активного фактора роста гепатоцитов (hgf)
AU2017340387A1 (en) 2016-10-04 2019-05-02 University Of Florida Research Foundation, Inc. Targeted effector proteins and uses thereof
JP6968451B2 (ja) * 2017-01-17 2021-11-17 バイオアプリケーションズ インコーポレイテッドBioapplications Inc. 植物細胞における目的タンパク質の発現のための組換えベクター
WO2018160865A1 (en) 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
WO2019075062A1 (en) 2017-10-11 2019-04-18 University Of Florida Research Foundation MODIFIED GAL-1 PROTEINS AND USES THEREOF
SG11202006169PA (en) * 2017-12-29 2020-07-29 Helixmith Co Ltd Adeno-associated virus (aav) vector having hybrid hgf gene introduced thereto
WO2020068798A1 (en) 2018-09-24 2020-04-02 Guo Jimin Living mammalian cells modified with functional modular nanoparticles
US20220220176A1 (en) * 2019-01-28 2022-07-14 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof
US12577282B2 (en) 2019-02-28 2026-03-17 University Of Florida Research Foundation, Incorporated Galectin-1/ galectin-3 chimeras and multivalent proteins
US12208164B2 (en) 2019-02-28 2025-01-28 Unm Rainforest Innovations Modular metal-organic polyhedra superassembly compositions
CN110452298A (zh) * 2019-08-26 2019-11-15 桂林医学院 一种肝靶向配体及其在脂质体制剂中的应用
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
JP7716399B2 (ja) * 2019-11-01 2025-07-31 ブイオーアール バイオファーマ インコーポレーテッド 抗－ｃｄ４５抗体及びそのコンジュゲート
CN114107490B (zh) * 2020-08-26 2024-06-21 北京仁诚神经肿瘤生物技术工程研究中心有限公司 评价患者对met抑制剂敏感性的试剂盒
WO2024119750A1 (en) * 2022-12-06 2024-06-13 Peking University Nucleic acid encoding human hgf and use thereof
CN119613527B (zh) * 2024-12-30 2026-02-06 江苏三仪生物工程有限公司 鸡肝细胞生长因子的截短突变体及其在防治肝脏相关疾病方面的用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3847770A (en) * 1972-04-10 1974-11-12 Continental Can Co Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4687610A (en) * 1986-04-30 1987-08-18 E. I. Du Pont De Neumours And Company Low crystallinity polyester yarn produced at ultra high spinning speeds
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5354566A (en) * 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6077697A (en) * 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
AU765703B2 (en) * 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
AU763513B2 (en) * 1998-04-16 2003-07-24 Genentech Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
US7393823B1 (en) * 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
WO2005016966A2 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
AU2005245896A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
WO2006119510A2 (en) * 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
JP2009515521A (ja) * 2005-11-10 2009-04-16 レセプター バイオロジックス， インコーポレイテッド レセプターアイソフォームおよびリガンドアイソフォームの産生のための方法

Also Published As

Publication number Publication date
WO2007058776A2 (en) 2007-05-24
KR20080082629A (ko) 2008-09-11
NO20082564L (no) 2008-08-11
JP2009515520A (ja) 2009-04-16
AU2006315825A1 (en) 2007-05-24
CN101356189A (zh) 2009-01-28
US20070161081A1 (en) 2007-07-12
EP1954714A2 (en) 2008-08-13
CA2628928A1 (en) 2007-05-24
WO2007058776A3 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
WO2007058776A3 (en) Hepatocyte growth factor intron fusion proteins
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
IL258880A (en) Diarylhydantoin compounds
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
MX336807B (es) Composiciones y metodos para producir una composicion.
AR061170A1 (es) Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
EA201001639A1 (ru) Композиции и способы их получения и применения
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
EA200802213A1 (ru) Способы лечения заболеваний крови
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
DK1771474T3 (da) Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
UA100840C2 (ru) Композиция для лечения вирусного гепатита
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX2010002557A (es) Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo.
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
DE602005001688D1 (de) Aufbereitung von Aldesleukin zur pharmazeutischen Verwendung
DE602006017882D1 (de) Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine
WO2007088051A3 (en) Modulation of mdl-1 activity for treatment of inflammatory disease
ATE475408T1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung
EP2216043A4 (en) USE OF GSE24.2 INDUCTOR AGENTS FOR DEVELOPING PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH CELL SENESCENCE

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]